We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-2.41%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.27B
AUM Growth
+$961M
Cap. Flow
+$1.18B
Cap. Flow %
36.01%
Top 10 Hldgs %
52.28%
Holding
50
New
10
Increased
18
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$156M
2
UHS icon
Universal Health Services
UHS
+$156M
3
CRL icon
Charles River Laboratories
CRL
+$108M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$99.9M
5
GSK icon
GSK
GSK
+$94.8M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$62.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$35.3M
3
INCY icon
Incyte
INCY
+$33.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$32.7M
5
EVH icon
Evolent Health
EVH
+$30.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.38%
2 Technology 1.96%
3 Consumer Discretionary 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
26
Align Technology
ALGN
$12.2B
$41.4M 1.27%
200,000
+100,000
+100% +$25.7M
MDT icon
27
Medtronic
MDT
$111B
$40.4M 1.24%
+500,000
New +$44.9M
XRAY icon
28
Dentsply Sirona
XRAY
$2.45B
$40.1M 1.23%
1,415,000
+165,000
+13% +$5.64M
SNY icon
29
CALL
Sanofi
SNY
$104B
$38M 1.16%
+1,000,000
New +$44.6M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
$34.2M 1.05%
+250,000
New +$40.7M
QTRX icon
31
Quanterix
QTRX
$189M
$33.1M 1.01%
3,000,000
+1,858,300
+163% +$23.6M
ZIMV
32
DELISTED
ZimVie
ZIMV
$25.7M 0.79%
2,600,000
+600,000
+30% +$9.68M
NUVA
33
DELISTED
NuVasive, Inc.
NUVA
$21.9M 0.67%
500,000
– –
EXEL icon
34
Exelixis
EXEL
$13.3B
$21.2M 0.65%
1,350,000
-300,000
-18% -$5.8M
PTON icon
35
Peloton Interactive
PTON
$2.42B
$20.8M 0.64%
+3,000,000
New +$30.5M
INGN icon
36
Inogen
INGN
$164M
$20M 0.61%
825,000
– –
GKOS icon
37
Glaukos
GKOS
$10.6B
$18.6M 0.57%
350,000
+162,978
+87% +$8.41M
CSII
38
DELISTED
Cardiovascular Systems, Inc.
CSII
$18M 0.55%
1,300,000
+359,600
+38% +$5.34M
ZYME icon
39
Zymeworks
ZYME
$1.75B
$17.6M 0.54%
2,865,000
+865,000
+43% +$5.21M
COLL icon
40
Collegium Pharmaceutical
COLL
$955M
$16.8M 0.52%
1,050,000
– –
OSUR icon
41
OraSure Technologies
OSUR
$277M
$16.1M 0.49%
4,250,000
– –
NSTG
42
DELISTED
NanoString Technologies, Inc.
NSTG
$12.8M 0.39%
1,000,000
+150,000
+18% +$2.08M
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12.6M 0.38%
500,000
-1,000,000
-67% -$27.7M
OSH
44
DELISTED
Oak Street Health, Inc.
OSH
$12.4M 0.38%
+506,000
New +$13.4M
PBYI icon
45
Puma Biotechnology
PBYI
$439M
$10M 0.31%
4,235,000
– –
EVH icon
46
Evolent Health
EVH
$459M
– –
-1,000,000
Closed -$30.7M
EXAS
47
DELISTED
Exact Sciences
EXAS
– –
-300,000
Closed -$11.8M
PACB icon
48
Pacific Biosciences
PACB
$367M
– –
-424,600
Closed -$1.88M
TSVT
49
DELISTED
2seventy bio
TSVT
– –
-48,600
Closed -$642K
SDC
50
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
– –
-1,000,000
Closed -$1.04M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Camber Capital Management held 50 positions worth $3.27B, up 42% from $2.3B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Camber Capital Management deployed $1.18B of net new capital in Q3 2022, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was Charles River Laboratories: 500,000 shares worth $98.4M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $62.3M trimmed.

  • Camber Capital Management's largest Q3 2022 buy was Charles River Laboratories: 500,000 shares worth $98.4M.
  • Camber Capital Management added most to Sanofi in Q3 2022, an estimated $156M increase.
  • Camber Capital Management's biggest Q3 2022 reduction was BioMarin Pharmaceuticals, cutting an estimated $62.3M.
  • Camber Capital Management fully exited Evolent Health in Q3 2022, selling an estimated $30.7M.
  • Camber Capital Management's ten largest holdings make up 52% of its $3.27B portfolio in Q3 2022.
  • Camber Capital Management opened 10 new positions and closed 5 in Q3 2022.
  • Camber Capital Management's portfolio value rose 42% quarter-over-quarter to $3.27B.

Based on Camber Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.